Andras Perl

Research activity per year

Fingerprint

Dive into the research topics where Andras Perl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

10 Active
87 Finished

A Phase 1b/2 Study of AZD0120 (GC012F), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Refractory Systemic Lupus Erythematosus (SLE) D8313C00001
Perl, A. (PI)
10/1/25 → 09/30/26
Upstate Medical University
Project: Research
Ntrust-1: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CARNK) Cell Therapy, in Subjects with Autoimmune Disease
Perl, A. (PI)
Nkarta Incorporated
08/12/25 → 08/11/26
Upstate Medical University
Project: Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Dapirolizumab Pegol In Study Participants With Moderately To Severely Active Systemic Lupus Erythematosus
Perl, A. (PI)
UCB Biopharma SPRL
08/11/25 → 08/10/26
Upstate Medical University
Project: Research
SLE Treatment with N-acetylcysteine
Perl, A. (PI), Perl, A. (PI) & Coman, I.-L. (CoI)
National Inst of Arthritis Musculoskeletal & Skin
06/1/25 → 05/31/26
Upstate Medical University
Project: Research
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus
Perl, A. (PI)
Zenas BioPharma Incorporated
04/18/25 → 04/17/26
Upstate Medical University
Project: Research

140 Article
48 Review article
12 Chapter
9 Editorial
More

Endosome traffic in rheumatic diseases: mechanistic insights and therapeutic opportunities
Perl, A., Mar 2026, In: Nature Reviews Rheumatology. 22, 3, p. 165-184 20 p.
Upstate Medical University
Research output: Contribution to journal › Review article › peer-review
1 Scopus citations
Cell type-specific regulation of the pentose phosphate pathway during development and metabolic stress-driven autoimmune diseases: Relevance for inflammatory liver, renal, endocrine, cardiovascular and neurobehavioral comorbidities, carcinogenesis, and aging
Banki, K. & Perl, A., Apr 30 2025, In: Autoimmunity Reviews. 24, 5, 103781.
Upstate Medical University
Research output: Contribution to journal › Review article › peer-review
14 Scopus citations
IgG and IgM Anti-Phosphatidylserine/Prothrombin Complex Antibody Detection May Improve Classification Accuracy of Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome
Donath, C., Kahlown, S., Suo, L., Banki, K. & Perl, A., Oct 2025, In: ACR Open Rheumatology. 7, 10, e70122.
Upstate Medical University
Research output: Contribution to journal › Article › peer-review

Open Access
5 Scopus citations
Potassium-Hydroxide-Based Extraction of Nicotinamide Adenine Dinucleotides from Biological Samples Offers Accurate Assessment of Intracellular Redox Status
Faludi, T., Krakko, D., Nolan, J., Hanczko, R., Patel, A., Oaks, Z., Ruggiero, E., Lewis, J., Wang, X., Huang, T. T., Molnar-Perl, I. & Perl, A., Nov 2025, In: International Journal of Molecular Sciences. 26, 21, 10371.
Upstate Medical University
Research output: Contribution to journal › Article › peer-review

Open Access
Spectral cytometry of rheumatoid arthritis patients implicates myeloid dendritic cells and granular HLA-DR+CD15+CD16+ cells in pro-inflammatory antigen presentation
Geier, C., Qudsi, H., Khairallah, E., Ben Gabr, J., Winchester, R. & Perl, A., 2025, In: Frontiers in Immunology. 16, 1596609.
Upstate Medical University
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations

Andras Perl

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

A Phase 1b/2 Study of AZD0120 (GC012F), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Refractory Systemic Lupus Erythematosus (SLE) D8313C00001

Ntrust-1: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CARNK) Cell Therapy, in Subjects with Autoimmune Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Dapirolizumab Pegol In Study Participants With Moderately To Severely Active Systemic Lupus Erythematosus

SLE Treatment with N-acetylcysteine

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus

Endosome traffic in rheumatic diseases: mechanistic insights and therapeutic opportunities

Cell type-specific regulation of the pentose phosphate pathway during development and metabolic stress-driven autoimmune diseases: Relevance for inflammatory liver, renal, endocrine, cardiovascular and neurobehavioral comorbidities, carcinogenesis, and aging

IgG and IgM Anti-Phosphatidylserine/Prothrombin Complex Antibody Detection May Improve Classification Accuracy of Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome

Potassium-Hydroxide-Based Extraction of Nicotinamide Adenine Dinucleotides from Biological Samples Offers Accurate Assessment of Intracellular Redox Status

Spectral cytometry of rheumatoid arthritis patients implicates myeloid dendritic cells and granular HLA-DR+CD15+CD16+ cells in pro-inflammatory antigen presentation

Andras Perl

Fingerprint

Collaborations and top research areas from the last five years

Grants & Projects

Research output